ES2151464T1 - Preparacion para aplicacion externa que comprende tranilast y procedimiento para producirla. - Google Patents

Preparacion para aplicacion externa que comprende tranilast y procedimiento para producirla.

Info

Publication number
ES2151464T1
ES2151464T1 ES97902588T ES97902588T ES2151464T1 ES 2151464 T1 ES2151464 T1 ES 2151464T1 ES 97902588 T ES97902588 T ES 97902588T ES 97902588 T ES97902588 T ES 97902588T ES 2151464 T1 ES2151464 T1 ES 2151464T1
Authority
ES
Spain
Prior art keywords
tranilast
preparation
external application
procedure
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES97902588T
Other languages
English (en)
Other versions
ES2151464T3 (es
Inventor
Masao Mori
Noriyasu Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Lead Chemical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Lead Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd, Lead Chemical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of ES2151464T1 publication Critical patent/ES2151464T1/es
Application granted granted Critical
Publication of ES2151464T3 publication Critical patent/ES2151464T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una preparación para aplicación externa que contiene una base acuosa que comprende tranilast, su sal, o una de sus mezclas en calidad de ingrediente activo, conteniendo la preparación para aplicación externa tranilast, caracterizada porque dicha base acuosa comprende un medio de disolución para disolver el tranilast, un dispersante, un adyuvante de absorción, un adhesivo y/o un agente mantenedor de la forma, y agua, y/o el ingrediente activo está disuelto en dicho medio de disolución y dispersado en la base acuosa por medio de dicho dispersante.
ES97902588T 1996-02-07 1997-02-06 Preparacion para aplicacion externa que comprende tranilast y procedimiento para producirla. Expired - Lifetime ES2151464T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4549396 1996-02-07

Publications (2)

Publication Number Publication Date
ES2151464T1 true ES2151464T1 (es) 2001-01-01
ES2151464T3 ES2151464T3 (es) 2002-12-16

Family

ID=12720933

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97902588T Expired - Lifetime ES2151464T3 (es) 1996-02-07 1997-02-06 Preparacion para aplicacion externa que comprende tranilast y procedimiento para producirla.

Country Status (11)

Country Link
US (1) US6239177B1 (es)
EP (1) EP0974350B1 (es)
JP (1) JP4154621B2 (es)
KR (1) KR100449939B1 (es)
CN (1) CN1081030C (es)
AT (1) ATE222759T1 (es)
DE (2) DE974350T1 (es)
DK (1) DK0974350T3 (es)
ES (1) ES2151464T3 (es)
PT (1) PT974350E (es)
WO (1) WO1997028793A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029744A1 (en) * 1996-02-15 1997-08-21 Kissei Pharmaceutical Co., Ltd. Neovascularization inhibitor
JP4865958B2 (ja) * 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
EP1559426B1 (en) * 2002-11-05 2011-02-09 Lead Chemical Co. Ltd. Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one
JP2004307364A (ja) * 2003-04-03 2004-11-04 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
CN100528153C (zh) * 2003-11-12 2009-08-19 立德化学株式会社 透皮吸收型脑保护剂
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention
US9066912B2 (en) * 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
US20050239892A1 (en) * 2003-11-21 2005-10-27 Trustees Of Tufts College Therapeutic avenathramide compounds
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
JP4590224B2 (ja) * 2004-07-20 2010-12-01 株式会社日本点眼薬研究所 トラニラストまたは薬理学的に許容される塩を含有する懸濁性医薬組成物
EP1782831B1 (en) * 2004-08-18 2011-10-19 Medrx Co., Ltd. External preparation
US7473738B2 (en) * 2004-09-30 2009-01-06 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
EP1824469A4 (en) * 2004-11-17 2008-07-30 Nuon Therapeutics Pty Ltd METHOD FOR MODULATING B-CELL FUNCTION
US20080009519A1 (en) * 2004-11-17 2008-01-10 Lawrence Steinman Method of modulating t cell functioning
JP2007051089A (ja) * 2005-08-18 2007-03-01 Medorekkusu:Kk 外用剤
WO2007046544A1 (ja) * 2005-10-21 2007-04-26 Medrx Co., Ltd. カルボキシル基を有する肥満細胞脱顆粒抑制剤と有機アミンとの塩を含有する外用剤
JP4959991B2 (ja) * 2006-03-03 2012-06-27 株式会社日本点眼薬研究所 トラニラストまたはその薬理学的に許容される塩を含有する懸濁性医薬組成物
MX352516B (es) 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
US8883190B2 (en) * 2006-12-01 2014-11-11 Wake Forest University Health Sciences Urologic devices incorporating collagen inhibitors
EP2030617A1 (en) * 2007-08-17 2009-03-04 Sygnis Bioscience GmbH & Co. KG Use of tranilast and derivatives thereof for the therapy of neurological conditions
CN101152164B (zh) * 2007-09-14 2011-04-06 李世荣 含有抗肥大细胞类药物的抗瘢痕外用贴膜及其制备方法
CN101152163B (zh) * 2007-09-14 2010-05-26 李世荣 含有激素类药物的抗瘢痕外用贴膜及其制备方法
EP2947073B1 (en) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
ES2759582T3 (es) * 2011-06-20 2020-05-11 Hisamitsu Pharmaceutical Co Parche que contiene lidocaína
JP6096021B2 (ja) * 2013-03-22 2017-03-15 ファイテン株式会社 顎関節症用外用剤
JP6558117B2 (ja) * 2014-08-19 2019-08-14 大正製薬株式会社 皮膚用剤
MA41266A (fr) * 2014-12-22 2017-10-31 Hisamitsu Pharmaceutical Co Cataplasme
WO2016136556A1 (ja) 2015-02-24 2016-09-01 久光製薬株式会社 パップ剤
CN104784101A (zh) * 2015-03-05 2015-07-22 中国药科大学制药有限公司 一种曲尼司特凝胶和软膏剂的处方及制备方法
KR101691472B1 (ko) 2015-07-06 2017-01-09 이광재 배낭에 탈착이 용이한 스틱 걸이
EP3503884B1 (en) * 2016-08-23 2021-07-21 Neurim Pharmaceuticals Ltd. Pharmaceutical composition for use in treating pruritus and/or itch
SG11201907139UA (en) 2017-02-03 2019-09-27 Certa Therapeutics Pty Ltd Anti-fibrotic compounds
CN108324724A (zh) * 2018-04-10 2018-07-27 苏州芝宇生物科技有限公司 一种克立硼罗可溶性膜制剂的制法及其应用
WO2020166665A1 (ja) 2019-02-14 2020-08-20 久光製薬株式会社 パップ剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124317A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
JPS62169723A (ja) * 1986-01-22 1987-07-25 Teisan Seiyaku Kk 徐放化製剤
JPS63238024A (ja) 1987-03-26 1988-10-04 Towa Yakuhin Kk 水難溶性薬物を含有する外用ゲル組成物
EP0303445A1 (en) * 1987-08-13 1989-02-15 Walton S.A. Clebopride transdermal patch
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JPH01294620A (ja) * 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
JPH07116029B2 (ja) * 1989-04-04 1995-12-13 キッセイ薬品工業株式会社 トラニラスト水溶液製剤
JPH0794378B2 (ja) * 1989-08-18 1995-10-11 久光製薬株式会社 エアゾール剤
JP3243564B2 (ja) * 1990-08-20 2002-01-07 リードケミカル株式会社 外用貼付剤
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
JPH05163222A (ja) 1991-12-18 1993-06-29 Kissei Pharmaceut Co Ltd コラーゲン過剰合成疾患治療剤
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
JPH06128153A (ja) * 1992-10-16 1994-05-10 Kissei Pharmaceut Co Ltd トラニラスト軟膏組成物およびその製造方法
AU667161B2 (en) * 1993-04-28 1996-03-07 Daiichi Pharmaceutical Co., Ltd. Butyrophenone transdermal compositions
PT698393E (pt) * 1993-05-19 2002-10-31 Hisamitsu Pharmaceutical Co Agente de solubilizacao e preparacao para uso externo contendo o mesmo
EP0709099A3 (en) * 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
JPH08295624A (ja) * 1995-04-26 1996-11-12 Read Chem Kk プラスター基剤、その製造方法、該基剤を使用した外用貼 付剤
FR2736048B1 (fr) * 1995-06-27 1997-08-01 Atochem Elf Sa Synthese du difluoromethane
CA2208332A1 (en) * 1996-06-20 1997-12-20 Hisamitsu Pharmaceuticals Co., Inc. Drug administration composition for iontophoresis

Also Published As

Publication number Publication date
CN1081030C (zh) 2002-03-20
EP0974350A1 (en) 2000-01-26
DE69715049D1 (de) 2002-10-02
JP4154621B2 (ja) 2008-09-24
KR100449939B1 (ko) 2004-11-20
CN1210462A (zh) 1999-03-10
ATE222759T1 (de) 2002-09-15
DE974350T1 (de) 2001-01-25
WO1997028793A1 (fr) 1997-08-14
KR19990082254A (ko) 1999-11-25
DK0974350T3 (da) 2002-11-25
EP0974350A4 (en) 2000-01-26
US6239177B1 (en) 2001-05-29
EP0974350B1 (en) 2002-08-28
DE69715049T2 (de) 2003-04-03
HK1018218A1 (en) 1999-12-17
PT974350E (pt) 2002-12-31
ES2151464T3 (es) 2002-12-16

Similar Documents

Publication Publication Date Title
ES2151464T3 (es) Preparacion para aplicacion externa que comprende tranilast y procedimiento para producirla.
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
ES2193515T3 (es) Composicion farmaceutica que comprende un compuesto triciclico con mejor estabilidad, absortividad y escaso potencial irritativo.
AR077412A2 (es) Formulacion farmaceutica composicon farmaceutica acuosa y formulacion farmaceutica acuosa liquida que comprende un anticuerpo
NO20004353L (no) Nye pyridazinderivater og medikamenter inneholdende disse som aktive ingredienser
PE20010400A1 (es) Formulacion de sal comun y moxifloxacina
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
CO5170479A1 (es) Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado saturado y un mono de ester de acido acrilico. .
DK0938471T3 (da) Fremstillingen og anvendelsen af ortho-sulfonamido-arylhydroxamsyrer som matrix-metalloproteinase- og TACE-inhibitorer
BR0302410A (pt) Composição de resposta deflagrada, composição de barreira de resposta deflagrada, dispositivo para a liberação deflagrada de um ou mais ingredientes ativos a um meio lìquido, e, processo para deflagrar a liberação de um ou mais ingredientes a um meio lìquido
CR6670A (es) Preparacion de acelerador de concreto
MX9401396A (es) Dispositivos distribuidores eclosionables osmoticos activados por el ph.
ECSP044974A (es) Formulación de suspensión oral estabilizada
NO20032388D0 (no) Salter av et isotiazol-4-karboksamid og anvendelse derav som anti-hyperproliferasjonsmidler
ES2183583T3 (es) Agente con efecto antidepresivo, que contiene pramipexol y sertralina.
ES2179103T3 (es) Composicion detergente.
CL2008001684A1 (es) Uso de un agente estimulador seleccionado entre el grupo de acidos uronicos, mananos, sales e hidratos de los mismos y mezclas de dichos compuestos, que sirve para preparar una composicion biopesticida que comprende un microorganismo antagonista, donde dicho agente estimula las propiedades antagonistas de microorganismo antagonista. (divisional solictud 422-02)
AR036294A1 (es) Modificador de la forma fisica de agentes agricolas basado en almidon dispersable en agua
BR0115080A (pt) Derivados de acila e sulfonila de 2-(trans-1,4-diaminocicloexil)-purinas 6,9-dissubstituìdas e o uso destes como agentes antiproliferativos
ATE552838T1 (de) Wässrige lösung mit aminoglykosid-antibiotikum und bromfenac
AR017925A1 (es) Una formulacion acuosa para verter, topicamente aceptable, adaptada para su aplicacion externa localizada en un animal, su uso y un metodo para formularla
AR020695A1 (es) Metodos para controlar macroinvertebrados en sistemas acuosos
AR020205A1 (es) Formulacion efervescente esterilizante.
NO20030998D0 (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
AR016473A1 (es) Preparado efervescente y procedimiento para su preparacion